

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061538 A3

(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 27/00 (2006.01)
A61K 48/00 (2006.01) A61P 29/00 (2006.01)
A61P 35/00 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/EP2004/014573

(22) International Filing Date:

20 December 2004 (20.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0330079.5 20 December 2003 (20.12.2003) GB

(71) Applicant (for all designated States except US): BIOIN-
VENT INTERNATIONAL AB [SE/SE]; Sölvegatan 41,
S-223 70 Lund (SE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): KIESSLING, Rolf

[SE/SE]; Rimmargatan 3, S-167 71 Bromma (SE). HOLM-
GREN, Lars [SE/SE]; Snäckvägen 14, S-167 53 Bromma
(SE).(74) Agent: PILKINGTON, Stephanie; Eric Potter Clarkson,
Park View House, 58 The Ropewalk, Nottingham NG1
5DD (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,


[Continued on next page]

(54) Title: VACCINE COMPRISING AN ANGIOMOTIN OR A POLYNUCLEOTIDE ENCODING AN ANGIOMOTIN AND
ITS USES FOR THE TREATMENT OF ANGIOGENIC-RELATED DISORDERS

A



B

(57) Abstract: A vaccine for preventing formation of blood
vessels, for example neoangiogenesis, as well as repressing
existing vascularization associated with tumors and other diseases,
comprising angiotin, for example as a whole molecule or
fragment thereof or encoded as a gene or mRNA, or administered
as dendritic cells (DC cells) expressing angiotin, which may be
utilized to generate immune responses to the angiotin molecule.
Inhibition of angiogenesis and delay in tumor outgrowth in animal
models of cancer is achieved.



FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:

23 February 2006